30,450 Shares in Zai Lab Limited (NASDAQ:ZLAB) Bought by DCF Advisers LLC

DCF Advisers LLC purchased a new stake in Zai Lab Limited (NASDAQ:ZLAB) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 30,450 shares of the company’s stock, valued at approximately $528,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allianz Asset Management GmbH boosted its stake in shares of Zai Lab by 26.1% in the fourth quarter. Allianz Asset Management GmbH now owns 679,524 shares of the company’s stock worth $18,571,000 after buying an additional 140,461 shares during the last quarter. Capital World Investors grew its stake in shares of Zai Lab by 8.9% during the 1st quarter. Capital World Investors now owns 5,684,180 shares of the company’s stock worth $91,061,000 after purchasing an additional 465,337 shares during the period. M&G Plc purchased a new position in shares of Zai Lab during the 1st quarter valued at approximately $7,266,000. Wellington Management Group LLP increased its holdings in shares of Zai Lab by 177.6% during the 4th quarter. Wellington Management Group LLP now owns 5,336,457 shares of the company’s stock valued at $145,845,000 after purchasing an additional 3,413,829 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Zai Lab by 51.1% in the 1st quarter. Russell Investments Group Ltd. now owns 293,783 shares of the company’s stock valued at $4,706,000 after purchasing an additional 99,355 shares during the period. 41.65% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Zai Lab news, insider Harald Reinhart sold 7,431 shares of Zai Lab stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $17.90, for a total transaction of $133,014.90. Following the sale, the insider now owns 62,619 shares of the company’s stock, valued at approximately $1,120,880.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Zai Lab news, insider Harald Reinhart sold 7,431 shares of the stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $17.90, for a total value of $133,014.90. Following the completion of the sale, the insider now owns 62,619 shares in the company, valued at approximately $1,120,880.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ying Du sold 23,939 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total value of $428,508.10. Following the transaction, the chief executive officer now owns 1,142,833 shares in the company, valued at $20,456,710.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,286 shares of company stock worth $975,291. 5.23% of the stock is owned by corporate insiders.

Zai Lab Stock Down 0.6 %

Shares of NASDAQ ZLAB opened at $21.09 on Friday. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $31.22. The company’s 50-day simple moving average is $18.74 and its 200-day simple moving average is $18.05. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -6.04 and a beta of 1.07.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.16). The firm had revenue of $100.50 million for the quarter, compared to analysts’ expectations of $94.46 million. Zai Lab had a negative return on equity of 37.96% and a negative net margin of 92.44%. Equities research analysts anticipate that Zai Lab Limited will post -2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ZLAB. JPMorgan Chase & Co. dropped their price target on shares of Zai Lab from $43.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, July 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Wednesday, August 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $58.97.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.